Loading...
XSHE
002252
Market cap6.23bUSD
Dec 05, Last price  
6.63CNY
1D
0.30%
1Q
-3.21%
Jan 2017
-71.29%
IPO
6.42%
Name

Shanghai RAAS Blood Products Co Ltd

Chart & Performance

D1W1MN
XSHE:002252 chart
P/E
20.07
P/S
5.38
EPS
0.33
Div Yield, %
1.01%
Shrs. gr., 5y
5.58%
Rev. gr., 5y
25.90%
Revenues
8.18b
+2.67%
303,192,604278,689,993309,976,913309,860,472387,519,941483,357,124567,385,772662,676,897496,359,5581,319,735,2302,013,321,6292,326,250,3481,927,748,4251,804,235,3992,584,983,9822,761,682,0364,287,726,7496,567,198,5817,963,958,5668,176,460,048
Net income
2.19b
+23.25%
51,242,49750,711,18081,769,205104,790,807135,663,016185,498,269200,354,617225,013,842143,794,617510,854,9401,442,414,3011,613,153,629835,828,5880607,893,7111,323,711,0551,294,510,0501,880,090,0661,779,476,9302,193,293,367
CFO
-482m
L
54,016,44753,584,846175,710,568107,642,052116,011,121200,209,539178,028,545263,464,6880465,961,164762,420,968638,223,427264,949,553262,500,811872,694,4701,168,847,1461,294,013,2191,725,596,0632,277,884,080-482,055,042
Dividend
Sep 30, 20240.037 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, human fibrinogen, human thrombin and human fibrin sealant, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. It also provides testing services for blood products, vaccines, diagnostic reagents, and testing equipment. The company also exports its products to Southeast Asia and Latin America. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.
IPO date
Jun 23, 2008
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT